Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/31663
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17756/20057 (89%)
Visitors : 7858182      Online Users : 574
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item:

    Title: Clinical benefits of antimicrobial de-escalation in adults with community-onset monomicrobial Escherichia coli, Klebsiella species and Proteus mirabilis bacteremia
    Authors: Lee, Ching-Chi
    Wang, Jiun-Ling
    Lee, Chung-Hsun
    Hung, Yuan-Pin
    Hong, Ming-Yuan
    Tang, Hung-Jen
    Ko, Wen-Chien
    Contributors: Madou Sin Lau Hosp, Dept Internal Med, Div Crit Care Med
    Chang Jung Christian Univ, Coll Hlth Sci, Grad Inst Med Sci
    Natl Cheng Kung Univ,Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med
    Natl Cheng Kung Univ, Coll Med, Dept Med
    Natl Cheng Kung Univ Hosp, Dept Emergency Med
    Tainan Hosp, Minist Hlth & Welf, Dept Internal Med
    Chi Mei Med Ctr, Dept Med
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    Keywords: De-escalation
    Escherichia coli
    Klebsiella species
    Proteus mirabilis
    Date: 2017-09
    Issue Date: 2018-11-30 15:52:01 (UTC+8)
    Publisher: Elsevier Science Bv
    Abstract: The clinical benefits of an antimicrobial de-escalation strategy were compared with those of a noswitch strategy in bacteremic patients. Adults with community-onset monomicrobial Escherichia coli, Klebsiella species and Proteus mirabilis bacteremia treated empirically using broad-spectrum betalactams, including third-generation cephalosporins (GCs), fourth-GC or carbapenems, were treated definitively with first-or second-GCs (de-escalation group), the same regimens as empirical antibiotics (no-switch group), or antibiotics with a broader-spectrum than empirical antibiotics (escalation group). The eligible 454 adults were categorized as the de-escalation (231 patients, 50.9%), no-switch (177, 39.0%), and escalation (46, 10.1%) groups. Patients with de-escalation therapy were more often female, had less critical illness and fatal comorbidity, and had a higher survival rate than patients in the other two groups. After propensity score matching in the de-escalation and no-switch groups, critical illness at onset (Pitt bacteremia score = 4; 16.5% vs. 12.7%; P = 0.34) or day 3 (2.5% vs. 2.5%; P = 1.00), fatal comorbidity (16.5% vs. 21.5%; P = 0.25), time to defervescence (4.6 vs. 4.7 days; P = 0.89), hospital stays (11.5 vs. 10.3 days; P = 0.13) and 4-week crude mortality rate (4.4% vs. 4.4%; P = 1.00) were similar. However, lower antibiotic cost (mean: 212.1 vs. 395.6 US$, P < 0.001) and fewer complications of bloodstream infections due to resistant pathogens (0% vs. 5.1%, P = 0.004) were observed in the de-escalation group. De-escalation to narrower-spectrum cephalosporins is safe and cost-effective for adults with community-onset EKP bacteremia stabilized by empirical broad-spectrum beta-lactams. (C) 2017 Elsevier B. V. and International Society of Chemotherapy. All rights reserved.
    Relation: International Journal of Antimicrobial Agents, v.50, n.3, pp.371-376
    Appears in Collections:[Dept. of Health and Nutrition (including master's program)] Periodical Articles

    Files in This Item:

    File Description SizeFormat

    All items in CNU IR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback